ArticleIntestinal Failure (New York, N.Y.)
Development of a registry to evaluate immobilized lipase cartridge use in pediatric patients with short bowel syndrome/intestinal failure.
Article in Intestinal Failure (New York, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Retrospective chart review of immobilized lipase cartridge use in children with short bowel syndrome.Journal of pediatric gastroenterology and nutrition · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Over the past 4 years, outpatient use of an immobilized lipase cartridge (ILC) (RELiZORB®; Alcresta Therapeutics) in pediatric patients with intestinal failure (IF) and short bowel syndrome (SBS) has increased. Although ILC use has been associated with improved fat absorption and enteral feeding tolerance in patients with exocrine pancreatic insufficiency and cystic fibrosis, there are no published reports of ILC use in patients with IF. Materials and methods: This prospective direct-to-patient observational registry collects real-world data regarding medical history, growth, quality of life, and progression towards enteral autonomy in pediatric patients with IF/SBS receiving enteral nutrition administered through an ILC. Eligible patients identified by a registry clinical coordinator are given the option to enroll in the registry. Data collected for the registry includes caregiver-as-proxy patient-reported outcome questionnaires, and clinical data from routine clinic visits for each patient for up to one year. A Registry Steering Committee provides oversight and reviews the scientific merit of proposals for subsequent data analysis. Results: The registry received Institutional Review Board approval in July 2024 with enrollment commencing shortly thereafter. As of October 11, 2024, 41 patients receiving care at 25 institutions in the United States were enrolled in the registry. Conclusion: It is anticipated that data collected through this registry will allow study of relevant research questions related to ILC use in patients with IF/SBS, including queries related to growth, progression towards enteral autonomy, and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.